Zylox-Tonbridge Medical Technology Co., Ltd. (Stock Code: 2190) has announced that its Board of Directors will convene on Tuesday, March 17, 2026. The primary agenda includes reviewing and approving the annual results for the year ended December 31, 2025, and considering a final dividend for 2025 if deemed appropriate.
The announcement, issued on March 2, 2026, notes that any other necessary business matters will also be discussed during the meeting. The Board is led by Chairman and Executive Director, Dr. Jonathon Zhong Zhao, with executive, non-executive, and independent non-executive directors collectively overseeing the company’s governance.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.